Ranibizumab
Also known as Lucentis (us), Razumab (india)
Ranibizumab implant is used to treat wet age-related macular degeneration (AMD; an eye disease that causes central vision loss [ability to see straight ahead]), diabetic macular edema (an eye disease caused by diabetes that can lead to vision loss) and diabetic retinopathy (damage to the eyes caused by diabetes).
Based on 30 units per month. US $34,768.92 vs India $250.50 per unit.
The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.
- Medicine savings over 6 months
- $6,213,316
- Estimated travel cost
- − $2,300
- Net savings after travel
- $6,211,016
Even after travel, you could come out ahead by about $6,211,016.
Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.
Ranibizumab is filled about 1.2K times a year under Medicare Part D. At the prices above, that works out to roughly:
Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.